Bristol-Myers Squibb Company (BMY)
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (83%) **Content type:** Clinical